Psilocybin
Optimi Health granted Natural Health Product Site Licence by Health Canada
VANCOUVER – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce…
VANCOUVER – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (MDMA), natural GMP-grade psilocybin, along with natural health product formulations, is pleased to announce the receipt of its Natural Health Product Site Licence following an assessment by the Natural and Non-prescription Health Products Directorate.
Under section 29 of the Natural Health Products Regulations, the expanded licensing allows for the manufacturing, packaging, and labelling of Natural Health Products at the Company’s Princeton, British Columbia facility.
Further, the licence also gives Optimi the ability to encapsulate products on site.
“This expands our ability to produce our products on site for global market distribution,” said Optimi CEO, Bill Ciprick. “This licence enables the Company to further diversify and leverage the potential of its existing manufacturing, processing and packaging capabilities to streamline fulfilment and reduce costs across its supply chain to support continued growth.”
Today’s announcement affirms Optimi’s commitment to supplying large scale research and development programs through its 10,000 square foot GMP compliant manufacturing facility.
Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (MDMA), natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
psilocybin mdma psychedelic cse optimi health optimi health canada research-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment